Verified ComparisonLast updated: 9 April 2026
BPC-157 vs TB-500
These two are often discussed together in research contexts. Neither is approved for human use; both are on WADA's prohibited list.
BPC-157
Recovery
4.5/ 5
A
TB-500
Recovery
4.4/ 5
A
Editor's note
BPC-157 has a deeper preclinical evidence base, particularly in tendon and gut models. TB-500 is mechanistically interesting but has narrower published support.
| Criterion | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic, derived from human gastric protein | Synthetic fragment of thymosin beta-4 |
| Preclinical evidence | Broad — tendon, gut, muscle, ligament | Wound healing, cardiac, corneal |
| Human clinical data | Very limited | Very limited |
| Regulatory status (AU) | Not approved | Not approved |
| WADA status | Prohibited (S0) | Prohibited (S2) |
Frequently asked questions
Yes — discussion in research literature often pairs them, though robust head-to-head human trials are not available.
Want to read the full reviews?